NCT03993704View on ClinicalTrials.gov

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

January 9, 2020

Study Completion Date

June 9, 2020

Conditions
Healthy
Interventions
DRUG

LHF-535

Oral suspension administered once daily for 14 days

Trial Locations (1)

Unknown

Centre for Clinical Studies, Melbourne

Sponsors

Lead Sponsor

Kineta Inc.
All Listed Sponsors
lead

Kineta Inc.

INDUSTRY

collaborator

Wellcome Trust

OTHER